Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Peripheral blood stem cell collection with high dose etoposide]

H Nakagawa1, H Fujii, Y Ariyama

  • 1Third Dept. of Internal Medicine, Kyoto First Red Cross Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 1, 1995
PubMed
Summary

High-dose etoposide chemotherapy effectively mobilizes peripheral blood stem cells (PBSC) for collection. This PBSC mobilization shows promising antitumor effects in various cancers, including leukemia and lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A GC box in the bidirectional promoter is essential for expression of the human dihydrofolate reductase and mismatch repair protein 1 genes.

FEBS letters·1992
Same author

[Clinical significance of recombinant human granulocyte colony-stimulating factor (rG-CSF) in the chemotherapy of patients with malignant lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·1992
Same author

[Superficial and pedunculated signet ring cell carcinoma of the urinary bladder: a case report].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

Successful pancreatojejunal anastomosis for pancreatoduodenectomy.

Surgery, gynecology & obstetrics·1992
Same author

Polar glycosphingolipids in annelida. A novel series of glycosphingolipids containing choline phosphate from the earthworm, Pheretima hilgendorf.

The Journal of biological chemistry·1992
Same author

[Clinical statistical data of patients with abnormal hemoglobin].

Nihon rinsho. Japanese journal of clinical medicine·1992

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • High-dose chemotherapy regimens are often employed for treating various hematologic and solid tumors.
  • Mobilization of peripheral blood stem cells (PBSC) is crucial for rescuing patients after myeloablative therapy.
  • Etoposide is a commonly used chemotherapeutic agent, but its efficacy in mobilizing PBSC requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of high-dose etoposide in mobilizing peripheral blood stem cells (PBSC) for collection.
  • To assess the antitumor effects of this treatment protocol in patients with diverse malignancies.
  • To determine the kinetics of hematopoietic recovery following PBSC transplantation.

Main Methods:

  • Peripheral blood stem cells (PBSC) were collected from 24 patients with various malignancies (leukemia, lymphoma, myeloma, testicular tumor) treated with high-dose etoposide.

Related Experiment Videos

  • Recombinant human granulocyte-colony stimulating factor (G-CSF) was administered to aid stem cell mobilization.
  • PBSC were collected via apheresis, and colony-forming unit-granulocyte-macrophage (CFU-GM) counts were determined.

    • Main Results:

    • Successful PBSC collection, with adequate CFU-GM yields ( > 5 x 10(5)/kg in 73% of patients), was achieved after etoposide treatment.
    • Significant antitumor responses were observed: complete remission in leukemia patients, complete response (CR) in 2 and partial response (PR) in 7 lymphoma patients.
    • Hematopoietic recovery, indicated by absolute granulocyte count > 0.5 x 10(9)/l, occurred within 7-11 days (mean 8.6) after PBSC transplantation.

    Conclusions:

    • High-dose etoposide is an effective regimen for mobilizing PBSC, yielding sufficient stem cells for transplantation.
    • The treatment demonstrated notable antitumor activity across a spectrum of hematologic and solid tumors.
    • Rapid hematopoietic recovery post-transplantation suggests the clinical utility of this approach.